Ji HS. Research and analysis of circulating tumor cell detection in the diagnosis and treatment of gastric cancer. World J Gastrointest Oncol 2025; 17(3): 102329 [DOI: 10.4251/wjgo.v17.i3.102329]
Corresponding Author of This Article
Han-Shu Ji, Second Department of General Surgery, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou 061000, Hebei Province, China. hanshuji1701@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 102329 Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.102329
Research and analysis of circulating tumor cell detection in the diagnosis and treatment of gastric cancer
Han-Shu Ji
Han-Shu Ji, Second Department of General Surgery, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China
Author contributions: Ji HS contributed to the experiment, data analysis, manuscript writing and revision.
Supported by Hebei Provincial Health Commission Project, No. 20210876.
Institutional review board statement: The study was reviewed and approved by Cangzhou Central Hospital, No. 2020-094-02(Z).
Clinical trial registration statement: The registration identification number and the URL are not applicable to our article.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Han-Shu Ji, Second Department of General Surgery, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou 061000, Hebei Province, China. hanshuji1701@163.com
Received: October 31, 2024 Revised: November 27, 2024 Accepted: December 30, 2024 Published online: March 15, 2025 Processing time: 106 Days and 2.2 Hours
Abstract
BACKGROUND
Circulating tumor cells (CTCs) are crucial for improving our knowledge regarding tumor progress, prognosis, and recurrence possibility.
AIM
To evaluate the role of CTCs in the early diagnosis and treatment of gastric cancer.
METHODS
From June 2020 to December 2021, a randomized study was conducted in our institution involving 80 patients scheduled for surgery for gastric cancer. The patients were divided into two groups: A control group that was tested for traditional serum markers and a study group that was assessed for serum CTCs.
RESULTS
In the study cohort, CTC levels did not correlate significantly with patient age, gender, or degree of tumor differentiation (P > 0.05). However, there was a significant correlation with the tumor-node-metastasis stage of the tumor (P < 0.05). In the study group, the CTC diagnostic positivity rate was 62.50% (25 out of 40 patients), while the positivity rate for conventional serum markers in the control group was 47.50% (19 out of 40 patients). The positive detection rate in the study group was significantly higher than that of the control group (P < 0.05).
CONCLUSION
CTCs have slight invasion and high sensitivity and specificity, presenting great value for early clinical diagnosis of recurrence and metastasis. It will improve the deceleration of disease development and increase the survival rate.
Core Tip: Investigate the role of circulating tumor cells in the early detection and treatment of stomach cancer. Here, we discovered that circulating tumor cells had minimal damage, high sensitivity, and strong specificity, making them useful for early clinical identification of recurrence or metastasis, slowing the progression of patients’ disease, and improving patient survival rates.
